首頁 > 市場調查報告書 > 製藥

癌症

市場調查報告書

商品編碼

1633606

腫瘤伴同性診斷市場規模、佔有率及成長分析（按成分、適應症、技術、最終用戶和地區）- 產業預測，2025-2032 年

Companion Diagnostics for Oncology Market Size, Share, Growth Analysis, By Component (Products, Services), By Indication (Breast Cancer, Non-Small Cell Lung Cancer), By Technology, By End User, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月11日 | 出版商:

SkyQuest | 英文 172 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

腫瘤伴同性診斷市場規模預計在 2023 年達到 35 億美元，2024 年達到 39.6 億美元，2032 年達到 105.2 億美元，預測期間（2025-2032 年）的複合年成長率為 13%。

隨著個人化醫療（根據癌症患者的個人基因圖譜制定治療方案）的日益普及，伴同性診斷市場預計將顯著成長。醫學研究投入的增加和各種癌症發病率的上升將推動對這些診斷的需求，為腫瘤學領域的公司提供新的機會。此外，精準醫療技術的進步預計將進一步刺激需求。然而，複雜的法律規範、高昂的實施成本以及分子資料管理困難等挑戰可能會阻礙市場的發展。總體而言，在技術創新和不斷成長的治療需求的推動下，腫瘤伴同性診斷領域有望擴大。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲國家
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前 5 家公司對比
主要企業市場定位（2024年）
主要市場參與者所採用的策略
近期市場趨勢
公司市場佔有率分析（2024 年）
主要企業簡介
- 公司簡介
- 產品系列分析
- 按細分市場分析市場佔有率
- 收益與前一年同期比較（2022-2024 年）

主要企業簡介

Roche Holding AG（Switzerland）
Thermo Fisher Scientific Inc.（USA）
Agilent Technologies, Inc.（USA）
Abbott Laboratories（USA）
BioMerieux SA（France）
Siemens Healthineers AG（Germany）
Danaher Corporation（USA）
Foundation Medicine, Inc.（USA）
Myriad Genetics, Inc.（USA）
Guardant Health, Inc.（USA）
Exact Sciences Corporation（USA）
Illumina, Inc.（USA）
Becton, Dickinson and Company（BD）（USA）
Bio-Rad Laboratories, Inc.（USA）
Leica Biosystems（Germany）
Sysmex Corporation（Japan）
Horiba, Ltd.（Japan）
Invitae Corporation（USA）
NeoGenomics, Inc.（USA）

結論和建議

簡介目錄

Product Code: SQMIG35B2205

Companion Diagnostics for Oncology Market size was valued at USD 3.5 Billion in 2023 and is poised to grow from USD 3.96 Billion in 2024 to USD 10.52 Billion by 2032, growing at a CAGR of 13% during the forecast period (2025-2032).

The companion diagnostics market is expected to see significant growth due to the increasing popularity of personalized medicine, which tailors treatment based on individual genetic profiles in cancer patients. Rising investments in medical research, coupled with the growing incidence of various cancers, will enhance demand for these diagnostics, presenting new opportunities for companies in the oncology sector. Additionally, advancements in precision medicine technology are likely to drive further demand. However, challenges such as complex regulatory frameworks, high implementation costs, and difficulties in managing molecular data may impede market development. Overall, the companion diagnostics for oncology sector is poised for expansion, driven by both technological innovations and increasing treatment needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Diagnostics For Oncology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Diagnostics For Oncology Market Segmental Analysis

The global companion diagnostics for oncology market is segmented based on component, technology, end user, indication, and region. In terms of component, the market is segmented into products and services. In terms of end user, the market is segmented into hospitals, pathology/diagnostic laboratories, and academic medical centers. Based on indication, the market is bifurcated into breast cancer, non-small cell lung cancer, colorectal cancer, leukemia, melanoma, prostate cancer, and others. In terms of technology, the market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), immunohistochemistry (IHC), in situ hybridization (ISH)/fluorescence in situ hybridization (FISH), and other technologies. Based on region, the market is segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa.

Driver of the Companion Diagnostics For Oncology Market

The Companion Diagnostics for Oncology market is significantly driven by the advancement of precision medicine. As technologies in this field evolve rapidly, they are accompanied by substantial investments in medical research and development. This surge in investment is largely fueled by the increasing demand for personalized cancer therapies, which aim to reduce side effects and enhance treatment effectiveness. Consequently, this growing emphasis on tailored treatment approaches is expected to contribute to a heightened demand for companion diagnostics, positioning them as essential tools in the management and treatment of oncology patients moving forward.

Restraints in the Companion Diagnostics For Oncology Market

One significant restraint impacting the Companion Diagnostics for Oncology market is the regulatory challenges posed by governmental bodies and authorities. The stringent guidelines and mandates governing the development of new companion diagnostics can complicate the approval process, resulting in delays. This rigorous compliance framework may hinder innovation and slow the progression of the market. As regulatory hurdles become more pronounced, they could impede the timely introduction of novel diagnostics, ultimately affecting the growth potential of the companion diagnostics sector in the oncology field. Therefore, navigating these regulatory landscapes is crucial for advancing market development.

Market Trends of the Companion Diagnostics For Oncology Market

The Companion Diagnostics for Oncology market is witnessing a notable trend toward biomarker discovery as companies aim to enhance their business scope and maximize revenue generation. By employing advanced genomic and proteomic technologies, organizations are not only identifying new biomarkers but also facilitating personalized treatment approaches that align with the evolving landscape of precision medicine. This strategic focus on biomarker innovation promises to drive market growth significantly, catering to the increasing demand for targeted therapies and improving patient outcomes. As the market continues to expand, investment in biomarker research will be crucial to staying competitive and capitalizing on emerging opportunities.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Companion Diagnostics for Oncology Market Size by Component & CAGR (2025-2032)

Market Overview
Products
Services

Global Companion Diagnostics for Oncology Market Size by End User & CAGR (2025-2032)

Market Overview
Hospitals
Pathology/Diagnostic Laboratories
Academic Medical Centers

Global Companion Diagnostics for Oncology Market Size by Indication & CAGR (2025-2032)

Market Overview
Breast Cancer
Non-Small Cell Lung Cancer
Colorectal Cancer
Leukemia, Melanoma
Prostate Cancer
Others

Global Companion Diagnostics for Oncology Market Size by Technology & CAGR (2025-2032)

Market Overview
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Immunohistochemistry (IHC)
In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH)
Other Technologies

Global Companion Diagnostics for Oncology Market Size & CAGR (2025-2032)

North America (Component, End User, Indication, Technology)
- US
- Canada
Europe (Component, End User, Indication, Technology)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Component, End User, Indication, Technology)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Component, End User, Indication, Technology)
- Brazil
- Rest of Latin America
Middle East & Africa (Component, End User, Indication, Technology)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioMerieux S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Foundation Medicine, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Leica Biosystems (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Horiba, Ltd. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NeoGenomics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments